| ★ | Survey Shows Peptide Misinformation, Misuse Rising in US | | 108 | Estados Unidos | |
| 2 | Why Fewer Than Half of Referred Patients Reach Kidney Transplant Evaluation | | 217 | Estados Unidos | 64 |
| 13 | What Comes Next for PORT-77 as It Heads Toward Phase 2b/3? | | 196 | Estados Unidos | 60 |
| 12 | All 12 Tegoprubart Recipients Off External Insulin Following Islet Implant in Pilot Study | | 168 | Estados Unidos | 61 |
| 6 | AHA Publishes Results of Nationwide Initiative for Lp(a) Education and Awareness | | 161 | Estados Unidos | 61 |
| 1 | New Martin-Hopkins LDL-C-Estimating Equation Simplifies Implementation for Comparable Results | | 151 | Estados Unidos | 66 |
| 14 | GLP-1 Receptor Agonists Reshape CKD Treatment Sequencing, With Pranav Garimella, MD | | 151 | Estados Unidos | 60 |
| 16 | FIND-CKD Trial Poses Finerenone as a "Third Pillar" for Nondiabetic CKD | | 123 | Estados Unidos | 60 |
| 18 | AERIFY: Phase 3 Data Reveal Challenges, Potential of Itepekimab in COPD | | 105 | Estados Unidos | 59 |
| 9 | SYMPHONY-PE: Early Thrombectomy Improves Pulmonary Embolism Outcomes | | 86 | Estados Unidos | 61 |
| 5 | Bimekizumab Data Support Case for Earlier Intervention in HS | | 78 | Estados Unidos | 62 |
| 11 | How to Sequence Omalizumab, Dupilumab, and Remibrutinib in CSU | | 74 | Estados Unidos | 61 |
| 3 | 2026 Dyslipidemia Guidelines Redefine Treatment, Monitoring Strategies, With Roger Blumenthal, MD | | 71 | Estados Unidos | 63 |
| 7 | Looking Beyond ALP Response in PBC With Saroglitazar, With Raj Vuppalanchi, MD | | 68 | Estados Unidos | 61 |
| 17 | AI-CPA Plaque Assessment Results Consistent, Reproducible Among Observers | | 41 | Estados Unidos | 59 |
| 19 | What is the Link Between Atopic Dermatitis and Asthma? With Eingun James Song, MD | | 40 | Estados Unidos | 59 |
| 20 | AI-Powered ECG and Echo Could Shrink 2.5-Year Diagnostic Delay in PH | | 31 | Estados Unidos | 59 |
| 8 | Plaque Imaging and the TRANSFORM Trial in Myocardial Infarction | | 29 | Estados Unidos | 61 |
| 15 | How ABCG2 Inhibition Could Change EPP Disease Management | | 17 | Estados Unidos | 60 |
| 10 | Time to Minimum Residual C-Peptide As a Predictor of Treatment Efficacy in T1D | | 16 | Estados Unidos | 61 |
| 4 | BE HEARD EXT: Bimekizumab Shows Greater Benefit With Earlier Use in HS | | 14 | Estados Unidos | 62 |